Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Bazhenova on the Potential Approval of Lorlatinib for Patients With ALK-Positive NSCLC

Lyudmila Bazhenova, MD
Published: Monday, May 07, 2018



Lyudmila Bazhenova, MD, professor of clinical medicine, University of California, San Diego, discusses the potential approval of lorlatinib for patients with ALK-positive non–small cell lung cancer (NSCLC).

Lorlatinib data are only relevant for patients who have failed prior ALK inhibitors, says Bazhenova. The study of lorlatinib had a treatment-naïve cohort, so physicians should have an idea of how lorlatinib works in patients who have not been exposed to alectinib (Alecensa) or crizotinib (Xalkori). The randomized trial results have not been released yet, says Bazhenova.

Lorlatinib is running a head-to-head study against crizotinib, and it is very possible that in the future physicians may have another option for newly diagnosed patients. Bazhenova notes that the trial design of lorlatinib is very important. It had several cohorts, and some of the cohorts allowed patients who had received 2 or more prior ALK inhibitors. Physicians have some sense that lorlatinib could work following treatment with brigatinib (Alunbrig), alectinib, or ceritinib (Zykadia).
 


Lyudmila Bazhenova, MD, professor of clinical medicine, University of California, San Diego, discusses the potential approval of lorlatinib for patients with ALK-positive non–small cell lung cancer (NSCLC).

Lorlatinib data are only relevant for patients who have failed prior ALK inhibitors, says Bazhenova. The study of lorlatinib had a treatment-naïve cohort, so physicians should have an idea of how lorlatinib works in patients who have not been exposed to alectinib (Alecensa) or crizotinib (Xalkori). The randomized trial results have not been released yet, says Bazhenova.

Lorlatinib is running a head-to-head study against crizotinib, and it is very possible that in the future physicians may have another option for newly diagnosed patients. Bazhenova notes that the trial design of lorlatinib is very important. It had several cohorts, and some of the cohorts allowed patients who had received 2 or more prior ALK inhibitors. Physicians have some sense that lorlatinib could work following treatment with brigatinib (Alunbrig), alectinib, or ceritinib (Zykadia).
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x